However, emerging studies found that advanced HCC patients who exhibit a B-RAS mutation or DCP (des-γ-carboxyl prothrombin) are more likely to be multifocal, aggressive, and resistant to TKI therapies [44,45]. This evidence concerns the gene ACE and hepatocellular carcinoma.